Aclarion (NASDAQ:ACON) Downgraded by Wall Street Zen to “Sell”

Aclarion (NASDAQ:ACON) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Saturday.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Aclarion in a research report on Wednesday, January 21st. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Sell”.

Aclarion Trading Down 0.4%

Shares of Aclarion stock opened at $2.58 on Friday. The firm has a market capitalization of $2.19 million, a PE ratio of -0.17 and a beta of 1.44. Aclarion has a 12 month low of $2.34 and a 12 month high of $229.50. The business’s 50-day moving average price is $4.58 and its 200-day moving average price is $6.40.

Aclarion (NASDAQ:ACON) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($2.93) earnings per share for the quarter, missing the consensus estimate of ($2.64) by ($0.29). Aclarion had a negative return on equity of 67.53% and a negative net margin of 10,908.50%.The business had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.02 million. As a group, analysts predict that Aclarion will post -263.33 earnings per share for the current fiscal year.

About Aclarion

Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc and changed its name to Aclarion, Inc in December 2021.